Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with 

Although there have been many advances in the treatment landscape of 

-mutant CRC, there is still room for improvement, says Kopetz. Currently, a promising triplet therapy of BRAF, MEK, and EGFR inhibitors is being studied in this population.

In the randomized phase III BEACON study, the triplet of binimetinib, encorafenib, and cetuximab (Erbitux), is being evaluated in patients with metastatic 

V600E CRC whose disease has progressed after 1 or 2 prior regimens. Kopetz says that this combination demonstrated a promising response rate of about 48%, with a median progression-free survival of about 8 months.

Videos

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with 

About 5% of patients with metastatic CRC harbor a 

mutation. Overall, the subgroup has a poor prognosis, as these tumors are very aggressive and the therapies available are not effective, Kopetz says. Most patients who harbor a 

Over the last year, there was a recent addition to the standard-of-care regimen for these patients as a result of the findings from the SWOG 1406 trial. This randomized study investigated irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in 

-mutant metastatic CRC. Results showed an improvement in progression-free survival, and had improved disease control rates, Kopetz says. This regimen is now considered a standard therapy for second- and third-line treatment.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer. 

Scott Kopetz, MD, PhD, FACP

Articles

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC